title: Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis.
abstract: OBJECTIVE
  SEMA3B and SEMA3F are 2 closely related genes lying 80 kb apart on chromosome 3 that have been shown to suppress tumor formation in vivo and in vitro. Each gene has a single nucleotide polymorphism that results in a nonsynonymous coding change, rs2071203 (SEMA3B) and rs1046956 (SEMA3F), as well as noncoding single nucleotide polymorphisms.
  
  
  METHODS
  We performed a case-control study of 789 prostate cancer cases and 907 controls from 3 races/ethnicities to determine possible associations of 10 variants with prostate cancer risk or prognosis.
  
  
  RESULTS
  The risk of prostate cancer increased more than 2-fold in Hispanic men with TT alleles at rs2071203 in SEMA3B and with CC alleles for rs2072054 at the 5' end of SEMA3F (OR 2.13, 95% CI 1.12-4.04, p = 0.02 and OR 2.55, 95% CI 1.34-4.84, p = 0.0045, respectively). These 2 single nucleotide polymorphisms were also associated with a poor prognosis in Hispanic men (2.71 and 3.48-fold increased risk). A frequent G-C-G-G-A-T-C-C-T-G haplotype encompassing 10 SNPs was associated with an increased risk of prostate cancer and poor prognosis in Hispanic samples (OR 2.72, 95% CI 1.20-6.12, p = 0.016 and OR 3.32, 95% CI 1.21-9.10, p = 0.02). In nonHispanic white men the T-C-G-A-A-T-C-C haplotype was associated with a high Gleason score (OR 1.44, 95% CI 1.06-1.96, p = 0.021).
  
  
  CONCLUSIONS
  These data indicate that polymorphisms in SEMA3B and SEMA3F are associated with prostate cancer risk and poor prognosis in Hispanic and nonHispanic white men.
authors.affiliation: Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, Texas 78229-3900, USA.
authors.forename: Joke
authors.initials: J
authors.lastname: Beuten
authors.forename: Dawn
authors.initials: D
authors.lastname: Garcia
authors.forename: Timothy C
authors.initials: TC
authors.lastname: Brand
authors.forename: Xin
authors.initials: X
authors.lastname: He
authors.forename: Ivana
authors.initials: I
authors.lastname: Balic
authors.forename: Edith
authors.initials: E
authors.lastname: Canby-Hagino
authors.forename: Dean A
authors.initials: DA
authors.lastname: Troyer
authors.forename: Jacques
authors.initials: J
authors.lastname: Baillargeon
authors.forename: Javier
authors.initials: J
authors.lastname: Hernandez
authors.forename: Ian M
authors.initials: IM
authors.lastname: Thompson
authors.forename: Robin J
authors.initials: RJ
authors.lastname: Leach
authors.forename: Susan L
authors.initials: SL
authors.lastname: Naylor
mesh_terms: D000328:Adult; D001741:Black or African American; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D006630:Hispanic or Latino; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000235:genetics*; D008565:Membrane Proteins / Q000235:genetics*; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics*; D012307:Risk Factors; D039961:Semaphorins / Q000235:genetics*; D044465:White People
chemical_list: D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D009419:Nerve Tissue Proteins; C409766:SEMA3B protein, human; C491230:SEMA3F protein, human; D039961:Semaphorins